CDX-2, a new marker for adenocarcinoma of gastrointestinal origin.
CDX2-88 is a recently developed monoclonal antibody to the intestinal epithelia-specific nuclear transcription factor CDX2. CDX2 immunohistochemistry has recently been shown to be useful in establishing gastrointestinal origin in metastatic tumors and will likely become a useful addition to the standard panel of immunostains for carcinomas of unknown primary sites. This article reviews the previous studies of this new antibody.
Li
Melissa K
MK
Department of Pathology, University of Florida, Gainesville, Florida, USA.
Folpe
Andrew L
AL
D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D014408:Biomarkers, Tumor; D000071616:CDX2 Transcription Factor; D005770:Gastrointestinal Neoplasms / Q000378:metabolism* / Q000473:pathology; D018398:Homeodomain Proteins / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D015534:Trans-Activators
D014408:Biomarkers, Tumor; D000071616:CDX2 Transcription Factor; D018398:Homeodomain Proteins; D015534:Trans-Activators